Holanek, M.; Selingerova, I.; Bilek, O.; Kazda, T.; Fabian, P.; Foretova, L.; Zvarikova, M.; Obermannova, R.; Kolouskova, I.; Coufal, O.;
et al. Neoadjuvant Chemotherapy of Triple-Negative Breast Cancer: Evaluation of Early Clinical Response, Pathological Complete Response Rates, and Addition of Platinum Salts Benefit Based on Real-World Evidence. Cancers 2021, 13, 1586.
https://doi.org/10.3390/cancers13071586
AMA Style
Holanek M, Selingerova I, Bilek O, Kazda T, Fabian P, Foretova L, Zvarikova M, Obermannova R, Kolouskova I, Coufal O,
et al. Neoadjuvant Chemotherapy of Triple-Negative Breast Cancer: Evaluation of Early Clinical Response, Pathological Complete Response Rates, and Addition of Platinum Salts Benefit Based on Real-World Evidence. Cancers. 2021; 13(7):1586.
https://doi.org/10.3390/cancers13071586
Chicago/Turabian Style
Holanek, Milos, Iveta Selingerova, Ondrej Bilek, Tomas Kazda, Pavel Fabian, Lenka Foretova, Maria Zvarikova, Radka Obermannova, Ivana Kolouskova, Oldrich Coufal,
and et al. 2021. "Neoadjuvant Chemotherapy of Triple-Negative Breast Cancer: Evaluation of Early Clinical Response, Pathological Complete Response Rates, and Addition of Platinum Salts Benefit Based on Real-World Evidence" Cancers 13, no. 7: 1586.
https://doi.org/10.3390/cancers13071586
APA Style
Holanek, M., Selingerova, I., Bilek, O., Kazda, T., Fabian, P., Foretova, L., Zvarikova, M., Obermannova, R., Kolouskova, I., Coufal, O., Petrakova, K., Svoboda, M., & Poprach, A.
(2021). Neoadjuvant Chemotherapy of Triple-Negative Breast Cancer: Evaluation of Early Clinical Response, Pathological Complete Response Rates, and Addition of Platinum Salts Benefit Based on Real-World Evidence. Cancers, 13(7), 1586.
https://doi.org/10.3390/cancers13071586
